Investigational Drug Details
| Drug ID: | D357 |
| Drug Name: | Synbiotic |
| Synonyms: | Synbiotics |
| Type: | Supplement |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | 1678556-56-3, 943828-05-5 |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial on-going (SLCTR/2018/042) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0503 | IRCT20100524004010N23 | Not applicable | Not Recruiting | No Results Available | 18/04/2018 | 21 May 2018 | Details |
| L0647 | IRCT201012084010N4 | Phase 2/Phase 3 | Not Recruiting | No Results Available | 30/11/2012 | 22 February 2018 | Details |
| L0776 | SLCTR/2018/042 | Phase 0 | Recruiting | No Results Available | 31/12/2018 | 7 February 2022 | Details |
| L0869 | NCT02530138 | Phase 2/Phase 3 | Recruiting | No Results Available | 18/08/2015 | 31 August 2015 | Details |
| L0924 | NCT01791959 | Phase 2/Phase 3 | Not recruiting | No Results Available | 05/02/2013 | 19 February 2015 | Details |
| L0931 | NCT01680640 | Not applicable | Not recruiting | No Results Available | 24/08/2012 | 12 December 2020 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00526 | 35053205 | Biomolecules | Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. | Details |
| A00758 | 34978141 | Obes Rev | Human microbiome and metabolic health: An overview of systematic reviews. | Details |
| A00881 | 34943104 | Antioxidants (Basel) | The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation. | Details |
| A01475 | 34734369 | J Gastrointest Surg | The Role of Gut-Derived Lipopolysaccharides and the Intestinal Barrier in Fatty Liver Diseases. | Details |
| A01921 | 34561722 | Eur J Nutr | Effects of β-glucan, probiotics, and synbiotics on obesity-associated colitis and hepatic manifestations in C57BL/6J mice. | Details |
| A02082 | 34511051 | Benef Microbes | Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. | Details |
| A02267 | 34441497 | Foods | Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. | Details |
| A02552 | 34330514 | Clin Nutr ESPEN | Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. | Details |
| A02694 | 34280304 | Cochrane Database Syst Rev | Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. | Details |
| A03206 | 34090052 | Biomed Pharmacother | Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal model. | Details |
| A03556 | 33957682 | Semin Liver Dis | New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. | Details |
| A05227 | 33331485 | Arq Gastroenterol | GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). | Details |
| A06488 | 32859329 | Clin Nutr ESPEN | The effects of Bacillus coagulans supplementation in patients with non-alcoholic fatty liver disease: A randomized, placebo-controlled, clinical trial. | Details |
| A06688 | 32780531 | Mol Nutr Food Res | Lactobacillus rhamnosus GG and Oat Beta-Glucan Regulated Fatty Acid Profiles along the Gut-Liver-Brain Axis of Mice Fed with High Fat Diet and Demonstrated Antioxidant and Anti-Inflammatory Potentials. | Details |
| A06866 | 32717871 | Int J Mol Sci | Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. | Details |
| A07301 | 32550166 | J Diabetes Metab Disord | The landscape of microbiota research in Iran; a bibliometric and network analysis. | Details |
| A07686 | 32390701 | World J Gastroenterol | Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view. | Details |
| A08601 | 32044317 | Gastroenterology | Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity? | Details |
| A08776 | 31987796 | Gastroenterology | Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. | Details |
| A09184 | 31845054 | J Gastroenterol | Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. | Details |